Anti Infective Agents Impact in COVID-19 Pneumonia

Centre d'Investigation Clinique et Technologique 805132 enrolled

Overview

During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone. Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.

Study Type

OBSERVATIONAL

Enrollment

132

Conditions

COVID Pneumonia, Viral

Interventions

favorable outcomeDRUG

Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * aged over 18 years old * hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry, * admitted outside an intensive care unit, in a medicine ward Exclusion Criteria: * patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia

Locations (1)

Benjamin Davido

Garches, France

Outcomes

Primary Outcomes

Favorable outcome

After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.

Time frame: Assessed within 7 days after admission

Secondary Outcomes

Risk factors 1

Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome

Time frame: Assessed at day 1

Risk factors 2

Studying if comorbidities were associated with an unfavorable outcome

Time frame: Assessed at day 1

Interest of anti-infective agents

Studying whether any regimen was associated with a favorable outcome (including azithromycin)

Time frame: From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.